Fake News and Competitive Strategy

Posted by Malini Solanki

Jan 3, 2017 1:54:02 PM

The diagnostic industry provides essential information for healthcare, and is driven by medical technology, the aging population, and the complexity of disease. One sector, the global blood testing market, in 2015 was valued at $51.5 billion and is expected to grow to $62.9 billion by 2024. Understanding how to craft strategy in this market is critical, given the funding required for new ventures, and it is nuanced, given the often unusual business practices that can be employed by one's competitors. 

Read More

Topics: Competitive Intelligence, Pharma, Competitive Strategy

New Year's Resolutions for the Competitive Strategist

Posted by Ken Sawka

Dec 19, 2016 10:38:10 AM

As 2016 ends, few would argue that most businesses are in for a roller coaster ride in 2017.  The United States is set for a hard-right turn politically, the Brexit process is facing new uncertainties regarding its duration and manner, and accusations of Russian cyber espionage and China’s muscle-flexing in the Asia Pacific region foreshadow turbulence in international relations. Longer-term demographic shifts in developed and developing economies will continue to affect wealth patterns and create new consumption opportunities.  What are strategists to do?

Read More

Topics: Competitive Intelligence, Competitive Strategy, Early Warning

The Ever Shifting Pharmaceutical Marketplace – Biosimilars and Interchangeability

Posted by Varun Naik

Dec 12, 2016 10:22:27 AM

The FDA recently approved Amjevita (adalimumab-atto), Amgen’s adalimumab biosimilar product for seven inflammatory indications in adult patients1. It was the fourth biosimilar approved by the FDA, and was announced just days after approval was granted for Sandoz’s Erelzi (etanercept-szzs), an Enbrel® biosimilar. Both Enbrel® and Humira® are blockbuster drugs with worldwide revenues over $8.7 and $14 billion respectively and the introduction of related biosimilars will certainly impact their growth potential by providing patients with new and different options and greater access to treatments. Further, biosimilars are expected to generate considerable cost savings for patients and reduce the burden on healthcare expenses.

Read More

Strategies for Surving an Industry Downturn

Posted by Nathaniel Emmons

Dec 7, 2016 11:12:13 AM

Co-written by Diane Borska

In late October, GE announced that it is spinning off its oil and gas business and merging it with Baker Hughes, embarking on a strategy of convergence, expanding its offerings and therefore the potential revenue it can generate, to remain vibrant and viable in the current industry downturn. In 2014, GE Oil and Gas developed a business plan based on oil prices of approximately $100 per barrel, but by January 2016, oil prices plummeted to $27 a barrel, resulting in a 30% drop in profitability. Developing strategies for how to respond to downturn is critical.

Read More

Topics: Competitive Intelligence, Innovation, Industry Convergence, Competitive Strategy

Future Trends for Competing in the Furniture Industry

Posted by Fuld + Company

Dec 5, 2016 1:51:32 PM

The $96 billion U.S. furniture industry is in a tumultuous state, driven by changing consumer preferences and buying behavior, digital disruption, pricing pressures, multi-channel retail options, new online players, and the role of social media.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Competitive Strategy

Qualitative Methods Enrich Quantitative Data

Posted by Diane Borska

Oct 27, 2016 9:22:14 AM

Co-Written by Ola Jachtorowicz

Seventy-six percent of millennials want to drive an eco-friendly car. Ninety-two percent of students prefer physical books to e-readers. Ninety percent of senior executives confirm that customer experience is one of their top three priorities. Sixty-seven percent of U.S. manufacturing executives plan to increase investments in data analytics next year.

Data is king. Statistics and opinion polls accompany every article, analysis, and prediction. It’s difficult to find a claim without a piece of quantitative evidence behind it.

Read More

Topics: Competitive Intelligence, Fuld + Company, Competitive Strategy

Strategy for When Satisfied Customers Don’t Come Back

Posted by Christopher Dent

Oct 21, 2016 9:14:53 AM

A month ago, my wife and I celebrated our third wedding anniversary. As we celebrated, I thought back to the autumn of 2007 when we first met.

I was a single 20-something professional, less than a year removed from active duty in the Marine Corps and anticipating settling down and starting a family. Having tried the “bar scene” to no avail, I decided to join eHarmony. Six months later, having met my beautiful wife and extremely happy with the outcome of my time on the site, I closed my account.

As I reminisced, I glanced at the pile of magazines sitting on the coffee table. I wondered: how does a company like eHarmony stay in business when a successful outcome means its clients never need it again, as opposed to other businesses (like periodicals) where the value proposition is ongoing?

Read More

Topics: Competitive Intelligence, Brand Insights, Technology/Telecomm, Competitive Strategy

Upcoming Event: Ken Sawka Speaking at BU Questrom Health & Life Sciences Conference October 14th

Posted by Fuld + Company

Oct 12, 2016 1:40:45 PM

On Friday, October 14th, Fuld + Company CEO, Ken Sawka, is speaking at the Boston University Questrom School of Business's fourth annual Health & Life Sciences Conference. 

The Health & Life Sciences Conference is an annual, student-organized event that brings together a diverse audience of more than 350 students and professionals across all sectors of the US healthcare industry for valuable networking and comprehensive programming spanning from healthcare delivery and hospitals to pharmaceuticals and medical devices.

Read More

Topics: Events, Healthcare, Life Sciences

Social Media Has Changed the Trajectory of Corporate Scandals

Posted by Christopher Dent

Sep 28, 2016 10:24:56 AM

There is an old rule of thumb that for every letter a congressman receives, there are 50 people thinking the same thing who didn’t pick up a pen. For every customer who bothers to complain, 26 others remain silent (and buy your competitor’s product instead).

How many people does a Facebook comment represent? What about a like or a share?

Read More

Topics: Brand Insights, Manufacturing/Industrial, Competitive Strategy

Upcoming Event: FGH Academy of Competitive Intelligence Certification Program Chicago October 31-Nov. 4, 2016

Posted by Fuld + Company

Sep 14, 2016 12:10:04 PM

 Join Leonard Fuld, Dr. Ben Gilad, Jan Herring, and Dr. Helen Rothberg, in Chicago October 31-November 4 for their core and advanced certification coursesYou will be engaged, excited, and a bit over whelmed by these dynamic presenters.

Read More

Topics: Competitive Intelligence, Events, FGH Academy of Competitive Intelligence, Fuld, Leonard

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.